Anthony B. Evnin, PhD, is a Partner at Venrock, one of the original venture capital firms in the United States, which he joined in 1974. He currently serves on the Board of Directors of AVEO Pharmaceuticals, Cantel Medical, Infinity Pharmaceuticals, Juno Therapeutics, as well as two private companies. Dr. Evnin was formerly a director of over 40 companies, both public and private, in the life sciences area.
He is a member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee of The Jackson Laboratory, a member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University.
Prior to joining Venrock, Dr. Evnin was a Research Scientist and Group Leader at Union Carbide Central Research and the Director of Product Development at Story Chemical.
He received an AB in Chemistry from Princeton University and a PhD in Chemistry from the Massachusetts Institute of Technology.